The study, conducted by researchers with the Centers for Disease Control and Prevention (CDC), found that six bacterial ...

Medical honey proves effective against antibiotic-resistant bacteria, transforming wound care and offering hope in the fight ...

Recent worldwide emergence of CA-MRSA has prompted the development of several new antibiotics (see Table 2). In the past, as vancomycin became less effective against MRSA, clinicians turned to ...

Dalba vancin and oritavancin have shown bactericidal activity against MRSA, VRSA, VRE, and DRSP and are undergoing the final stages of clinical trials (Bradley, 2005; Hoffman-Roberts et al., ...

Increased VISA growth in diabetic infection Vancomycin is frequently used to treat MRSA-associated bacteremia. Infection with vancomycin intermediate-resistance S. aureus (VISA) strains are three ...

Ten projects at Queen’s are receiving support from the Canadian Institutes of Health Research to advance research that will have a high impact on health care knowledge and delivery.

Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin ...

Acurx Pharmaceuticals, Inc. ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today ...